Drug Profile
Solifenacin tartrate
Alternative Names: HIP-1503; Solifenacin tartrate - Hanmi PharmaceuticalLatest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Class Esters; Irritable bowel syndrome therapies; Isoquinolines; Quinuclidines; Small molecules; Urologics
- Mechanism of Action Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Overactive bladder
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for phase-I development in Overactive bladder in South Korea (PO)
- 19 Aug 2016 Phase-I clinical trials in Overactive bladder in South Korea (PO) (Hanmi Pharmaceutical pipeline, August 2016)
- 01 May 2016 Hanmi Pharmaceutical completes a phase I trial in Overactive bladder (In volunteers) in South Korea (PO) (NCT02940314)